Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15932157 | 0.79 | PIK3CD (0.52) | PIK3CDLMNACYP2C9 | |
| SCHEMBL15932152 | 0.79 | PIK3CD (0.52) | PIK3CDLMNACYP2C9 | |
| SCHEMBL13416632 | 0.79 | PIK3CD (0.52) | PIK3CDLMNACYP2C9 | |
| SCHEMBL890066 | 0.79 | PIK3CD (0.52) | PIK3CDLMNACYP2C9 | |
| SCHEMBL19701893 | 0.79 | PIK3CD (0.52) | PIK3CDLMNACYP2C9 | |
| SCHEMBL13184997 | 0.78 | ATM (0.33) | ATM | |
| SCHEMBL15314559 | 0.77 | PIK3CD (0.41) | PIK3CDLMNACYP2C9 | |
| SCHEMBL13291299 | 0.74 | PIK3CD (0.38) | PIK3CDLMNACYP2C9 | |
| SCHEMBL12829221 | 0.73 | ATM (0.31) | ATM | |
| SCHEMBL12829580 | 0.72 | ATM (0.30) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PIK3CD 601/4885ATM 4578/4885LMNA 3064/4885 |
| US-20100266543-A1 | LINKED DIBENZIMIDAZOLE ANTIVIRALS | EIF2AK2, ZC3HAV1, NSUN2 | PIK3CD 451/4885ATM 4808/4885LMNA 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.